Contineum’s PIPE-307 Misses RRMS Trial Goals but Retains Potential in Depression

Contineum Therapeutics’ experimental M1 receptor modulator, PIPE-307, did not achieve its primary or secondary goals in the Phase II VISTA trial for relapsing–remitting multiple sclerosis (RRMS). The study failed to show improvement in low-contrast letter acuity or in other key clinical and imaging measures. Developed with Johnson & Johnson, the drug will undergo further data analysis to assess any signals in exploratory endpoints, especially given the ongoing need for therapies that can support remyelination and repair neuronal damage in MS.

Despite this setback, analysts remain optimistic about PIPE-307’s prospects in major depressive disorder (MDD). Janssen is currently evaluating the drug in the Phase II Moonlight-1 trial, expected to report results in 2026. Experts note that its novel mechanism could offer an advantage in a crowded antidepressant landscape, despite challenges such as high placebo response rates. Safety findings from the RRMS trial also support its continued development. Contineum is meanwhile advancing its lead candidate, PIPE-791, into Phase II testing for idiopathic pulmonary fibrosis.

26-11-2025